尿透明质酸-透明质酸酶1联合检测对膀胱癌诊断和治疗的意义

目的:探讨尿透明质酸(HA)和透明质酸酶1(HYAL1)联合检验对膀胱癌诊断和治疗的意义。方法:取自40位膀胱肿瘤患者术前(40份)及术后(40份)尿液标本80份,另20份尿液取自对照组(包括正常人、泌尿生殖系其他疾病患者)。采用放射免疫标记技术和ELISA技术检测尿液HA和HYAL1水平,并对其结果进行讨论分析。结果:患者术前组中HYAL1水平是术后组的1.5倍(P<0.05),是对照组的2～4倍(P<0.05);而术前组中HA水平在G2/G3移行细胞癌患者中显著升高,是术后组的1.5倍(P<0.05),是对照组的1.5～3倍(P<0.05),但在G1级患者尿中无显著升高(P>0.05)。而HA HYAL1联检在膀胱癌诊断中具有较高的灵敏度(95%)、特异度(75%)和精确度(88.33%)。结论:HA HYAL1联检是诊断膀胱癌和手术评估的一种非侵入性、高灵敏度、高特异度的检测方法。

Significance of urinary HA-HYAL1 test in diagnosis and treatment of bladder cancer

Objective:To discuss the significance of urinary HA and HYAL1 levels as bladder cancer markers for the diagnosis and treatment in bladder cancer. Methods: 80 specimens from bladder carcinoma patients, including 40 pre-OPS and 40 post-OPS, were gathered for this study. Another 20 specimens from healthy individuals or patients with other genitourinary conditions(GU) were included as reference. The urinary HA and HYAL1 were measured by radioimmuno-label and ELISA assay. Results: Urinary HYAL1 levels from pre-OPS group elevated 1.5 times to the post-OPS group and 2～4 times when compared with the UC group. Urinary HA levels from pre-OPS group were 1.5 times higher than the post-OPS group and 1.5～3 times to the UC group in G2/ G3 bladder carcinoma while it did not elevate in G1 bladder carcinoma. HA-HYAL1 test revealed a higher response (95%), distinguished specificity(75%)and accuracy(88.33%) in this study. Conclusion: HA-HYAL1 test is a new method with non-invasion, higher sensitivity and specificity in diagnosing bladder and evaluating the operation.